(Q35097710)

6 August 2017

1 reference

title

Immunology and immunotherapy of colorectal cancer (English)

1 reference

6 August 2017

1 reference

1 reference

0 references

1 reference

Piero Dalerba

1

0 references

Chiara Castelli

object named as

Chiara Castelli

4

0 references

author name string

Cristina Maccalli

2

1 reference

6 August 2017

Chiara Casati

3

1 reference

6 August 2017

Giorgio Parmiani

5

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

46

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

33-57

1 reference

Spontaneous regression of cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Spontaneous resolution of histologically proven liver metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Model predicting survival in stage I melanoma based on tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Lymphocytic infiltration and survival in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

From Dukes through Jass: pathological prognostic indicators in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Total rectal resection and complete mesorectum excision followed by coloendoanal anastomosis as the optimal treatment for low rectal cancer: the experience of the National Cancer Institute of Milano

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Survival for colon and rectal cancer in a population-based cancer registry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Stromal eosinophilia in colonic epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Quantification of colonic lamina propria cells by means of a morphometric point-counting method

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Mast cells in colorectal neoplasias and premalignant disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Inflammation and cancer: back to Virchow?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Inflammatory cells and cancer: think different!

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The origin and function of tumor-associated macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Dendritic cell infiltration in colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Principles for adoptive T cell therapy of human viral diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Morphology of sporadic colorectal cancer with DNA replication errors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Histopathological identification of colon cancer with microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Limited heterogeneity in the T-cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Intraepithelial lymphocytes: exploring the Third Way in immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Regulation of cutaneous malignancy by gammadelta T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A major fraction of human intraepithelial lymphocytes simultaneously expresses the γ/δ T cell receptor, the CD8 accessory molecule and preferentially uses the Vδ1 gene segment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

CD4- and TCRalphabeta-positive T lymphocytes predominantly infiltrated into well-moderately differentiated colon adenocarcinoma tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

MHC antigens and tumor escape from immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Antitumor immunity at work in a melanoma patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Mechanisms of loss of HLA class I expression on colorectal tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Natural history of HLA expression during tumour development.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T cells in inflammatory bowel disease: protective and pathogenic roles

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Up-regulation of the Expression of Secretory Component and HLA Molecules in a Human Colonic Cell Line by Tumour Necrosis Factor-alpha and Gamma Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (Ii) in normal colorectal mucosa, adenoma and carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T-cell recognition of melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A listing of human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Characterization of human colon cancer antigens recognized by autologous antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Biological response to intrahepatic adoptive immunotherapy with autologous interferon activated macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

An explanation of the variable clinical response to interleukin 2 and LAK cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Tumor-specific T-bodies: towards clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Monoclonal antibody therapy for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Mechanism of action of trastuzumab and scientific update

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunology and immunotherapy of human cancer: present concepts and clinical developments

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Vaccines for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Cytokine gene transduction in the immunotherapy of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunotherapy for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunity against solid tumors?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Dendritic cell vaccination for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The makings of a tumor rejection antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T cell response to tumor antigens and its therapeutic use in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Anti-idiotype cancer vaccines: past and future

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Colorectal cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Detection and clinical importance of micrometastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

T-cell immunity in the induction and maintenance of a tumour dormant state

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Tumor-induced immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Impaired cytokine production in whole blood cell cultures from patients with colorectal carcinomas as compared to benign colorectal tumors and controls

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Nutrition and gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900159-2

7 January 2021

10.1016/S1040-8428(02)00159-2

Identifiers

DOI

1 reference

release_tgr2mysjbff4tp4ag645xh3biq

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tgr2mysjbff4tp4ag645xh3biq

24 November 2022

mapped directly with Wikidata item

1 reference